This is a strong clinical catalyst for GSK's oncology pipeline. The magnitude of OS benefit (54% risk reduction, 8.2-month median gain) and first-in-class B7-H3 ADC data de-risk the broader Ris-Rez program. Watch for the EMBOLD SCLC-301 pivotal readout next year and potential regulatory filings outside China. The stock may re-rate on pipeline optionality.
Price Chart
Executive Summary
GSK announced positive overall survival data from the ARTEMIS-008 Phase III trial of Ris-Rez (risvutatug rezetecan) in relapsed small cell lung cancer in China. Ris-Rez reduced the risk of death by 54% vs topotecan (HR 0.46, p<0.0001), with median OS of 18.5 months vs 10.3 months, and showed a favorable safety profile. This is the first Phase III data to demonstrate an OS benefit for a B7-H3 ADC in any tumor type, supporting GSK's global development program with pivotal data from the EMBOLD SCLC-301 trial expected next year.
Key Facts
- Ris-Rez reduced risk of death by 54% vs topotecan in relapsed SCLC (HR 0.46; 95% CI: 0.35-0.62, p<0.0001)
- Median OS: 18.5 months (Ris-Rez) vs 10.3 months (topotecan)
- Median PFS: 7.2 months vs 3.0 months (HR 0.33)
- Objective response rate: 58.3% vs 12.6%
- Grade 3+ TRAEs: 60.9% (Ris-Rez) vs 78.2% (topotecan)
- First Phase III data to show OS benefit for a B7-H3 ADC in any tumor type
- GSK holds ex-China rights; pivotal global data from EMBOLD SCLC-301 expected next year
Financial Impact
Positive Phase III OS data for Ris-Rez in SCLC, a high-unmet-need indication; potential peak sales could be significant but no revenue figures provided in filing
Risk Factors
- Data are from a China-only trial; global regulatory path and commercial uptake outside China are unproven
- Competitive landscape for B7-H3 ADCs is evolving with multiple developers
- Pivotal global data from EMBOLD SCLC-301 not yet available; execution risk remains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-008321 |
| Document: 0001654954-26-008321-index-headers.html | 0001654954-26-008321 |
| Document: 0001654954-26-008321-index.html | 0001654954-26-008321 |
| Document: 0001654954-26-008321.txt | 0001654954-26-008321 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access